MedTrace Logo

Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

NCT04214717 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-03-28

No results posted yet for this study

Summary

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

Conditions

Interventions

COMBINATION_PRODUCT

DC-CIK combined with Chemotherapy

Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.

DRUG

Chemotherapy

Patients will only receive Chemotherapy.

Sponsors & Collaborators

  • Yantai Yuhuangding Hospital

    lead OTHER

Principal Investigators

  • Peiwen Lian, PhD · Yantai Yuhuangding Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04214717 on ClinicalTrials.gov